ClinicalTrials.gg
RecruitingNCT05285735Updated Jan 30, 2024

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

An observational study in Pregnancy and Malaria, sponsored by Amivas (US), LLC. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Amivas (US), LLC · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
25
Ages
15 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.

Planned enrollment
13th of 15
25 · median 324
Started
2022
with 4 others
Observational
16 of 105
5 open now
Registered
93rd of 105
by date

Among the 105 studies in Malaria with a site in United States, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2022, is one of 16 observational ones, and was the 93rd registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 15 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Malaria with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective observational study in which a female patient who received IV Artesunate while pregnant can volunteer to provide information about her pregnancy and the outcome of her pregnancy. Information will be collected from patient's provider, the patient's obstetrician, the child's pediatrician, or other relevant healthcare provider.

Read the detailed description

Pregnant women or physicians treating pregnant women with severe malaria with IV Artesunate will become aware of the Pregnancy Registry via the product label, the Amivas Inc. website, or her physician. By calling 1-855-526-4827 (1-855-5AMIVAS) or contacting www.amivas.com/our-products, the patient or physician will be connected to the Pregnancy Registry Call Center. In France, the Collaborating-Investigators conducting the ARTEMUM observatory study have a wide information campaign among obstetrical wards, neonatal wards, Infectious Diseases wards, intensive care units (ICU), and parasitology hospital laboratories, through expert networks of infectious diseases specialists, obstetricians and pediatricians in University hospitals from the Paris Area and suburbs that concentrate 50-55% of malaria cases in France. They also collaborate with the National Research Center (NRC) for malaria and will capture voluntary reports by clinicians and microbiologists in the NRC network.

When contact is made to the call center, a trained staff member will acquaint the patient or treating physician with the goals and procedures of the study. If the patient agrees to participate in the study over the telephone, the patient's verbal consent will be documented, and the patient will be sent the study Consent Form that includes the consent for the patient's physician/obstetrician and the child's pediatrician to release medical information via email. If a physician is contacting the Call Center, s/he may be provided with this form to review, and the physician will be directed to ask the patient to telephone the Call Center to provide consent. With the patient's consent, the patient's physician/obstetrician will be contacted by a Call Center staff member and will be interviewed by a trained call center healthcare professional/pharmacist for information about the patient including demographics, malaria history, history of treatment, and initial pregnancy data. The Call Center will contact the patient's physicians (including obstetrician and infant's pediatrician, as appropriate) each trimester until delivery, and also at birth and 1 year after birth, to collect data on maternal adverse events (AEs), pregnancy outcome, fetal outcome, and infant outcome. Patients consented in France under the ARTEMUM study will undergo the consent process by the treating Physician. Anonymized data will be prospectively collected by a research technician under the supervision of a local manager in France.

Data collected by the call center will be sent to the Coordinating Center on a monthly basis for review and tracking of participants, then annually for inclusion in the interim or final report. Data collected as part of the ARTEMUM study will be provided in aggregate as summary tables to be included in the annual report.

03

Conditions studied

  • Pregnancy
  • Malaria

Browse trials for

Keywords

  • Artesunate
  • Pregnancy Registry
04

Who can participate

Ages eligible
15 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women worldwide who were or are being treated with IV Artesunate who can be properly consented to provide personal health information on her pregnancy and agree to provide health information on her fetus, neonate, and infant child will be included in the study. Although IV Artesunate is indicated for the treatment of severe malaria, women who were treated off label for another indication who received IV Artesunate while pregnant will be included in the study as well.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient received IV Artesunate
  • Patient was pregnant while receiving IV Artesunate
  • Patient was at least 15 years of age
  • Patient or legal guardian/representative gave consent for the study and to collect data from her physicians

Exclusion criteria

Exclusion Criteria

  • None
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
25 participants (estimated)
Target follow-up
21 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of pregnant females with high blood pressure

    Number of pregnant females with high blood pressure reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  2. Number of pregnant females with severe nausea

    Number of pregnant females with severe nausea reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  3. Number of pregnant females with vomiting

    Number of pregnant females with vomiting reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  4. Number of pregnant females with dehydration

    Number of pregnant females with dehydration reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  5. Number of pregnant females with diabetes (newly occurring)

    Number of pregnant females with diabetes (newly occurring) reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  6. Number of pregnant females with obesity/marked weight gain

    Number of pregnant females with obesity/marked weight gain reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  7. Number of pregnant females with anemia (newly occurring)

    Number of pregnant females with anemia (newly occurring) reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  8. Number of pregnant females with kidney or bladder infections

    Number of pregnant females with kidney or bladder infections reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  9. Number of pregnant females with vaginal bleeding

    Number of pregnant females with vaginal bleeding reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  10. Number of pregnant females with abruptio placenta

    Number of pregnant females with abruptio placenta reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  11. Number of pregnant females with placenta previa

    Number of pregnant females with placenta previa reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  12. Number of pregnant females with premature rupture of membranes

    Number of pregnant females with premature rupture of membranes reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  13. Number of pregnant females with preterm labor

    Number of pregnant females with preterm labor reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  14. Number of pregnant females with ectopic pregnancy

    Number of pregnant females with ectopic pregnancy reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  15. Number of pregnant females with molar pregnancy

    Number of pregnant females with molar pregnancy reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  16. Number of pregnant females who died

    Number of pregnant females who died reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  17. Number of pregnant females with spontaneous abortions/miscarriage

    Number of pregnant females with spontaneous abortions/miscarriage reported in medical record

    Time frame: Up to 20 weeks

  18. Number of pregnant females with elective terminations

    Number of pregnant females with elective terminations reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  19. Number of fetal deaths/stillbirths

    Number of fetal deaths/stillbirths reported in medical record

    Time frame: From 20 weeks to study completion

  20. Number of premature live births (<37 weeks)

    Number of premature live births (\<37 weeks) reported in medical record

    Time frame: Up to 37 weeks

  21. Number pregnant females with with live term births

    Number pregnant females with with live term births reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  22. Number of pregnant females with normal vaginal delivery or C-section

    Number of pregnant females with normal vaginal delivery or C-section reported in medical record

    Time frame: Through study completion, an average of 40 weeks

  23. Number of newborns with low birth weight (<2500 grams)

    Number of newborns with low birth weight (\<2500 grams)

    Time frame: At birth

  24. Number of newborns with heart and circulation defects

    Number of newborns with heart and circulation defects reported in medical record

    Time frame: At birth

  25. Number of newborns with genital and urinary tract defects

    Number of newborns with genital and urinary tract defects reported in medical record

    Time frame: At birth

  26. Number of newborns with nervous system and eye defects

    Number of newborns with nervous system and eye defects reported in medical record

    Time frame: At birth

  27. Number of newborns with Club foot

    Number of newborns with Club foot reported in medical record

    Time frame: At birth

  28. Neonate mean body weight (kg)

    Neonate mean body weight (kg)

    Time frame: 1 month

  29. Infant mean body weight (kg)

    Infant mean body weight (kg)

    Time frame: 12 months

  30. Number of infants who sit unattended or without support

    Number of infants who sit unattended or without support from medical record

    Time frame: 12 months

  31. Number of infants who pick up small objects with thumb-finger grasp

    Number of infants who pick up small objects with thumb-finger grasp from medical record

    Time frame: 12 months

  32. Number of infants who say "Dada" or "Mama" nonspecifically

    Number of infants who say "Dada" or "Mama" nonspecifically from medical record

    Time frame: 12 months

  33. Number of infants who look for dropped objects or objects hidden by parents

    Number of infants who look for dropped objects or objects hidden by parents from medical record

    Time frame: 12 months

  34. Neonate mean body length (cm)

    Neonate mean body length (cm)

    Time frame: 1 month

  35. Neonate mean head circumference (cm)

    Neonate mean head circumference (cm)

    Time frame: 1 month

  36. Infant mean recumbent weight (kg)

    Infant mean recumbent weight (kg)

    Time frame: 12 months

  37. Infant mean weight-for-length ratio (kg/cm)

    Infant mean weight (kg) divided by body length (cm)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • 4C Pharma Solutions
    Piscataway, New Jersey 08854, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Jun 2029, 84 months after the start.

Of 93 observational studies under Malaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 84 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Mar 18, 2022
StartActual
Jun 8, 2022
Primary completionEst.
Jun 8, 2029
CompletionEst.
Jul 1, 2029
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05285735
Lead sponsor
Amivas (US), LLC
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Jun 8, 2022
Primary completion
Jun 8, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jan 30, 2024

Study contacts

Katrina Riggs
Contact
kriggs@fastttrackresearch.com
3017622609
Bryan Smith, MD
principal investigator · Amivas (US), LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion